Phase 1 study of OKI-179, an oral class 1-selective depsipeptide HDAC inhibitor, in patients with advanced solid tumors: Final results. Phase Ia study of CBP-1008, a bi-specific ligand drug conjugate ...
The alternative text for this image may have been generated using AI.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results